in non-small cell lung cancer confers significant stage-independent survival dis- Expression of novel molecules
W. Zhou, et al. Cancer Letters 483 (2020) 75–86 [35] 2016Alzheimer\'sdiseasefactsandfigures.AlzheimersDement.12(2016)459-509. Hernandez, PTENand PI3K/AKT in non-small-cell lung cancer, Pharmacogenomics [36] M. Reck, D.F. Heigener, T. Mok, J.C. Soria, K.F. Rabe, Management of non-small- 16 (2015) 1843–1862. cell lung cancer: recent developments, Lancet 382 (2013) 709–719. [45] O.David,H.LeBeau,A.R.Brody,M.Friedman,J.Jett,Phospho-Aktoverexpression [37] S. Ashida, M. Furihata, T. Katagiri, K. Tamura, Y. Anazawa, H. Yoshioka, et al., in non-small cell lung cancer confers significant stage-independent survival dis- Expression of novel molecules, MICAL2-PV (MICAL2 prostate cancer variants), in- advantage, Chest 125 (2004) 152S. creaseswithhighGleasonscoreandprostatecancerprogression,Clin.Canc.Res.12 [46] S.Wang,Y.Zheng,Z.He,W.Zhou,Y.Cheng,C.Zhang,SH2B1promotesNSCLCcell (2006) 2767–2773. proliferation through PI3K/Akt/mTOR signaling cascade, Canc. Cell Int. 18 (2018) [38] E....